SLC6A3 and Lewy body dementia: Several biomarkers are used clinically in the differential diagnosis of DLB, with dopamine transporter imaging proven to be effective in detecting early nigrostriatal changes (5, 6) and [123I]metaiodobenzylguanidine myocardial scintigraphy to detect changes in the peripheral sympathetic nervous system (7).